drugset

drugset / Trial / NCT00423644

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

NCT00423644 ↗

Phase 2 Unknown 17 enrolled Alaunos Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Timeline

Start: 2007-01
Primary completion: 2013-12
Completion: 2013-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darinaparsin	Small molecule	420 mg/m2	—

Indications